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Abstract
Background:  Acute-phase response involves the simultaneous altered expression of serum
proteins in association to inflammation, infection, injury or malignancy. Studies of the acute-phase
response usually involve determination of the levels of individual acute-phase serum proteins. In
the present study, the acute-phase response of patients with epithelial (EOCa) and germ-line
(GOCa) ovarian carcinoma was investigated using the gel-based proteomic approach, a technique
which allowed the simultaneous assessment of the levels of the acute-phase serum high abundance
proteins. Data obtained were validated using ELISA and immunostaining of biopsy samples.
Results: Enhanced expression of clusterin (CLU), α1-antitrypsin, haptoglobin and leucine rich
glycoprotein was detected in all patients. However, the levels of α1-antichymotrypsin (ACT) was
only enhanced in EOCa patients, while patients with GOCa were typically characterized by
elevated levels of ceruloplasmin but lower levels of α2-HS glycoprotein. The enhanced expression
of CLU in EOCa and GOCa patients and up-regulated expression of ACT specifically in EOCa
patients were confirmed by ELISA. Immunohistochemical staining of biopsy samples of EOCa and
GOCa patients demonstrated correlation of the acute-phase protein expression.
Conclusion: Patients with EOCa and GOCa demonstrated distinctive aberrant expression of
serum and tissue high abundance acute-phase proteins compared to negative control women.
Background
The expression of serum proteins can be analysed concur-
rently by using the gel-based proteomic technology. This
is appropriate for studying the acute-phase response,
which involves the simultaneous altered expression of
serum proteins in association to inflammation, infection,
injury or cancer [1]. Many of the proteomic studies on
serum or plasma have been performed using samples that
were depleted of albumin and/or immunoglobulins in
order to analyze serum proteins of lower abundance [2-4].
However, a number of serum proteins including those
that have been used clinically or experimentally have been
demonstrated to adhere strongly to albumin and immu-
noglobulins [5]. These serum proteins were also removed
in experiments involving depletion of the high abundance
proteins, and thus, may affect interpretation of the results.
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Moreover, recent studies using rat plasma have revealed
that depletion of high abundance proteins only reduced
the dynamic range of plasma proteome by two to three
orders of magnitude. Removal of albumin, IgG, IgM,
transferrin, fibrinogen, haptoglobin (HAP) and α1-antit-
rypsin (AAT) from rat plasma leads to the unmasking of
only a few proteins and was still far from being able to
detect the low abundance proteins [6].
Our previous gel-based proteomic studies performed on
unfractionated whole serum samples of patients with dif-
ferent types of cancer have highlighted the altered expres-
sion of selective high abundance acute-phase reactant
proteins. Breast cancer patients were reflective of their dif-
ferential expression of serum α1-antichymotrypsin (ACT),
clusterin (CLU) and complement factor B (CFB) [7], while
patients with nasopharyngeal carcinoma expressed the
sole elevated levels of serum ceruloplasmin (CPL) [8].
Although the expression of AAT, α1-B glycoprotein (ABG)
and anti-thrombin III were consistently altered in patients
with endometrial adenocarcinoma (EACa), squamous
cell cervical carcinoma (SCCa) and adenocervical carci-
noma (ACCa), CLU was specifically up-regulated in
patients with EACa, whereas patients with SCCa and
ACCa were typically characterized by the up-regulated
expression of zinc α-2-glycoprotein (ZAG) [9].
In the present study, we have analyzed the expression of
high abundance acute-phase reactant proteins in sera of
patients who were newly diagnosed with epithelial ovar-
ian carcinoma (EOCa) and germ line ovarian carcinoma
(GOCa) using the gel-based proteomic approach. The
expression of the proteins was validated using ELISA as
well as by immunohistochemical staining of cancer tis-
sues from the patients.
Results
Serum Protein Profiles
When unfractionated whole sera of negative control
women unaffected by cancer (n = 30) were subjected to 2-
DE and silver staining under the resolving conditions
adopted in the present study, the high abundance pro-
teins that were detected include albumin, the heavy and
light chains of IgA, IgG and IgM, two groups of CLU (CLU
and CLU2), AHS, ABG, AAT and its fragment AATf, ACT,
CPL, β chains of HAP (HAP), leucine rich glycoprotein
(LRG) and hemopexin (HPX) (Figure 1, panel A). When
the 2-DE experiments were performed on sera of 42
patients with ovarian carcinoma (n = 13 for GOCa and n
= 29 for EOCa) who were newly diagnosed and untreated,
comparable profiles were obtained for most of the
resolved proteins. Panels B and C of Figure 1 demonstrate
typical 2-DE serum protein profiles of patients with GOCa
and EOCa, respectively. In both subtypes of the ovarian
carcinoma patients, three additional clusters of proteins
including CLU, cleaved β chains of HAP (HAPc) and a dif-
ferent cluster of AATf spots were detected.
Identification of Serum Proteins
With exception of LRG, all the other serum high abun-
dance clusters of protein spots have been previously iden-
tified by mass spectrometry and/or protein sequencing [7-
10]. In cases of AAT and CLU, different forms of the serum
proteins (AATf and CLU2) were also detected in the
present study. Identities of LRG, AATf and CLU2 were
confirmed by subjecting the protein spot clusters to
MALDI-MS analysis and database search (Table 1). Some
of the AATf spots within the cluster were identified using
MALDI-MS/MS with 28 sequences of peptides correlating
to the protein.
Image Analysis of 2-DE Gels
When the clusters of protein spots were analyzed by a den-
sitometry software, higher expression of CLU (p  <
0.0001), AAT (p < 0.001), AATf (p < 0.0001), LRG (p <
0.0001), CPL (p < 0.05), HAP (p < 0.0005) and HAPc (p <
0.005) was detected in sera of patients with GOCa (Figure
2). However, the expression of AHS (p < 0.05) appeared to
be lower in GOCa patients compared to the negative con-
trols. There was no significant difference in the expression
of CLU2, HPX and ABG between the GOCa patients and
the negative controls.
Similar analysis performed on serum images of patients
with EOCa also revealed the aberrant expression of serum
proteins. Higher expression of ACT (p < 0.0001), CLU (p
< 0.005), AAT (p < 0.0001), AATf (p < 0.0001), LRG (p <
0.0001), HAP (p < 0.0005) and HAPc (p < 0.0001) was
significantly detected (Figure 2). There was no significant
difference between the expression of AHS, CLU2, HPX
and ABG of patients with EOCa compared to the negative
controls.
Analysis of Protein Expression by ELISA
For confirmation of the aberrantly-expressed proteins in
the sera of GOCa and EOCa patients, competitive ELISA
was carried out using antisera against ACT, CLU, CPL,
AHS, AAT and HAP. Figure 3 demonstrates the results of
the competitive ELISA performed on sera of negative con-
trol women, GOCa patients and EOCa patients. Higher
levels of CLU (p < 0.0001) were significantly detected in
sera of the GOCa patients compared to the negative con-
trol women. In the case of EOCa patients, the expression
of CLU (p < 0.0001), ACT (p < 0.0001) and HAP (p < 0.05)
was significantly higher than that of the negative controls.
However, the expression of AAT, AHS and CPL in both
cohorts of patients was not significantly different from
that of the control women.Proteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
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Typical 2-DE serum protein profiles of the negative control women and patients with GOCa and EOCa Figure 1
Typical 2-DE serum protein profiles of the negative control women and patients with GOCa and EOCa. Unfrac-
tionated serum samples of patients and negative controls were subjected to 2-DE and silver staining. Panel A demonstrates a 
typical representative 2-DE serum protein profile of negative control women. Panels B and C demonstrate typical representa-
tive unfractionated serum protein profiles of the patients with GOCa and EOCa, respectively. The aberrantly expressed pro-
teins are marked in brackets for panels B and C. For all panels, the acidic sides of the 2-DE gels are to the left and relative 
molecular mass declines from the top.
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Analysis of Tissue Protein Expression by 
Immunohistochemical Staining
The expression of CPL, CLU, ACT and AAT was deter-
mined for 17 biopsy samples of patients with ovarian car-
cinoma. Among 17 tissue samples, two were from patients
diagnosed with GOCa and 15 were from patients diag-
nosed with EOCa. The overall results and staining pat-
terns of the biopsy samples of patients with clinically- and
histopathologically-confirmed ovarian carcinoma are
summarized in Table 2. The expression of CPL and CLU
was positively-stained consistently in all ovarian carci-
noma tissues that were studied. However, ACT was posi-
tively-stained in 13 biopsy samples (two cases of GOCa
and 11 cases of EOCa), while positive-staining for AAT
was detected in ten biopsy samples (one case with GOCa
and nine cases with EOCa) (Figure 4).
Table 1: MS identification of protein spot clusters from 2-DE serum protein profiles.
Serum
 proteinsa
Accession
 numberb
Theoretical
 Mr (da)/pI
No. of p
eaks
matched 
(No. of
  peaks searched)
MASCOT
 score
% of 
sequence
 coverage
LRG gi | 112892 38178/6.45 8(11) 67 22
CLU2 gi | 4502905 4877/6.27 6(10) 50 16
AATf gi | 1703025 46707/5.37 8(14) 68 20
AATf c gi | 7546268 37565/5.5 28d 307 50
a Spot ID are as in Figure 1. Mr: nominal mass
b Accession numbers are from the MASCOT database http://www.matrixscience.com
c Spots within cluster identified by MALDI-MS/MS analysis
d Number of peptides matched
Percentage of volume contribution of 2-DE detectable serum proteins of control women (Con) and patients with EOCa and  GOCa Figure 2
Percentage of volume contribution of 2-DE detectable serum proteins of control women (Con) and patients 
with EOCa and GOCa. Percentage of volume contribution (%vol) of protein spots was analyzed by ImageMaster™ 2D Plat-
inum Software Version 5. Analysis was restricted to twelve clusters of protein spots.
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Discussion
EOCa and GOCa are two different types of ovarian cancer
that affect women of different age groups. While EOCa is
more common in pre-menopausal women, GOCa is pre-
dominantly a cancer that affects adolescents and young
women under 30 years of age. EOCa arises from the epi-
thelium or outer cells covering the ovary and it accounts
for more than 90% of ovarian cancer cases. GOCa differs
Analysis of serum protein expression by competitive ELISA Figure 3
Analysis of serum protein expression by competitive ELISA. Competitive ELISA was preformed using sheep/goat anti-
human ACT, AHS, CLU, CPL, AAT and HAP as primary antibodies. Analyses were performed in triplicate. Relative expression 
of serum proteins in GOCa and EOCa patients is defined as percentage (%) of up- or down regulation from that of negative 
controls.

                         Con          GOCa          EOCa                       Con          GOCa          EOCa 
                       Con          GOCa         EOCa
           Con          GOCa        EOCa                       Con          GOCa          EOCa 
                      Con          GOCa          EOCa                        Con          GOCa                   Con          GOCa          EOCaProteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
Page 6 of 11
(page number not for citation purposes)
Immunohistochemical analysis of protein expression in ovarian tissues of normal donors and ovarian carcinoma patients Figure 4
Immunohistochemical analysis of protein expression in ovarian tissues of normal donors and ovarian carci-
noma patients. Immunohistochemical staining was performed using antisera to (A) CPL, (B) CLU, (C) ACT, and (D) AAT. 
Panels A and B demonstrate immunohistochemical stains showing strong positive CPL and CLU expression in ovarian cancer 
(OCa) tissues but negative expression in normal ovarian tissues (internal positive control). Panels C and D demonstrate immu-
nohistochemical stains showing moderate positive ACT and strong positive AAT expression in OCa tissues, respectively, but 
weak positive expression in normal ovarian tissues.
(A)
(B)
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              Normal tissues                                                 OCa tissues Proteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
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from EOCa in that it arises from the cells that mature into
eggs that are formed inside the ovary [11].
By using 2-DE and image analysis, we have demonstrated
the alteration of serum high abundance proteins expres-
sion involving higher expression of CLU, AAT, AATf, LRG,
HAP and HAPc in sera of both cohorts of patients with
EOCa and GOCa. However, the expression of ACT was
only enhanced in EOCa patients while patients with
GOCa demonstrated lower levels of AHS and enhanced
expression of CPL compared to the negative controls.
Since the controls used in the present study were serum
samples obtained from normal healthy individuals, we
cannot totally exclude the possibility that the aberrant
protein expression may be due to inflammation of the
ovary rather than cancer. Nevertheless, similar prelimi-
nary experiments performed on patients with inflamma-
tion of the ovary indicated that the high abundance acute-
phase protein expression was markedly different from
those of the EOCa and GOCa patients (data not shown).
The elevated levels of CLU in both cohorts of EOCa and
GOCa patients and enhanced expression of ACT only in
patients with EOCa were confirmed by ELISA. ELISA also
confirmed the up-regulated expression of HAP in EOCa
patients but was not able to demonstrate the difference in
the expression of HAP and CPL in patients with GOCa as
well as the up-regulated expression of AAT in both cohorts
of the ovarian carcinoma patients. CLU and CPL were pos-
itively-detected in the biopsy samples of all patients tested
while staining of ACT was positive in 13/17 patients' tis-
sues analyzed.
CLU is implicated in diverse physiological functions
including the regulation of cell growth and survival [12].
Its enhanced expression has been described in breast can-
cer [8], hepatocellular carcinoma [13], desmoplastic
melanoma [14], colorectal cancer [15], bladder cancer
[16], lymphomas [17] as well as ovarian cancer [18]. Mul-
tiple isoforms of CLU, arise from various post-transla-
tional modification processes, have been detected [19]. In
the present study, two groups of CLU were detected in the
2-DE protein profiles. While the main group of CLU was
up-regulated in the sera of EOCa and GOCa patients,
CLU2 was not abnormally expressed. These results are
compatible with the recent findings of Rodriguez-Pineiro
and coworkers in their studies on colorectal cancer [15].
Our data also emphasized the expression of CLU in the
malignant tissues of all ovarian carcinoma patients ana-
lyzed.
Like CLU, CPL is another protein reported to be elevated
in sera of patients with diverse types of cancer. Elevated
levels of CPL has been described in studies on thyroid can-
cer [20], melanoma [21], lymphoma [22], kidney and uri-
nary tract cancer [23], gastrointestinal cancer [24], cervical
cancer [9,25], uterine cancer [9,26] and nasopharyngeal
carcinoma [8]. When bound to copper, CPL induces ang-
iogenesis, which supports growth of tissues and tumors
[27]. In the present study, detection of CPL in tissues of all
patients tested is indicative of the strong association of
angiogenesis with malignancy. The up-regulated expres-
sion of CPL was also significantly detected by 2-DE in the
GOCa patients but not in patients with EOCa.
ACT, a member of the serine proteinase inhibitor family,
is an acute-phase response protein [28]. Its association
with cancer is rather restrictive unlike CLU and CPL. Pre-
vious studies have shown that the levels of ACT were also
elevated in patients with breast cancer [7,29], and the
excessive ACT was likely to be synthesized by the breast
epithelial cells [30,31]. Hence, ACT may be also synthe-
sized by the epithelial cells of the ovary which explains its
observed up-regulated expression in sera of patients with
EOCA but not GOCa patients both by using 2-DE and
ELISA. In the tissues of the ovarian cancer patients, how-
ever, ACT was positively-stained in both the two biopsy
samples of GOCa patients tested as well as 76% of the
biopsy samples of EOCa patients.
The enhanced levels of AAT in sera of ovarian carcinoma
patients that were detected in our 2-DE studies were not
supported by the results of our ELISA experiments. Never-
theless, the up-regulated expression of AAT, which was
always linked to liver diseases [32], as well as its N-termi-
nal fragment, has been previously reported in the sera of
patients with cancers of the prostate, lung and breast [33]
although this association was not well understood. Simi-
larly, our 2-DE experiments also detected the up-regulated
expression of AATf, which were likely to be generated by
the proteolysis of AAT, in both EOCa and GOCa patients.
This appears to indicate that AAT was actively processed
within the cancer microenvironment. AAT was also posi-
tively-detected in 59% biopsy samples of patients ana-
lyzed, inclusive of both subtypes of ovarian carcinoma.
Like AAT, ELISA was not able to confirm the different
altered expression of AHS and HAP in sera of ovarian car-
cinoma patients by 2-DE studies. Our previous reports
have indicated that the 2-DE proteomic approach is more
Table 2: Analysis of protein expression by immunohistochemical 
staining of patients' biopsy samples.
Antibody GOCa EOCa Total
CPL 2/2 15/15 17/17
CLU 2/2 15/15 17/17
ACT 2/2 11/15 13/17
AAT 1/2 9/15 10/17Proteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
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sensitive than ELISA with many of the proteins analysed
showed more than ten-fold difference in sensitivity
between the two techniques [7,8]. One possibility for the
difference in sensitivity as well as the discrepancy in the
results is that the up-regulated proteins may have trig-
gered the humoral immune response in patients and
caused binding of the patients' antibodies to the serum
proteins. Such binding would certainly interfere with the
ELISA and reduce its sensitivity.
The correlation between HAP expression and ovarian car-
cinoma has been widely reported [34,35]. Studies have
also shown both the α- and β-subunits of HAP to be sig-
nificantly increased in early stage ovarian carcinoma
patients [36,37]. In the case of AHS, our data showed
down-regulation of the protein in sera of both cohorts of
EOCa and GOCa patients. The low concentration of AHS
in ovarian carcinoma serum may be associated with
depressed cellular immunity [38] and short-term mortal-
ity of patients similar to that reported for patients with
liver cancer [39].
Due to the lack of antiserum, we were not able to validate
the results of the 2-DE experiments on overexpression of
LRG in sera and tissues of EOCa and GOCa patients. LRG,
a secretory protein of unknown function [40], has been
noted for its acute-phase protein characteristics [41]. We
have also recently reported the up-regulated expression of
LRG in sera of patients with endometrial adenocarcinoma
[9].
Our present data obtained from patients with ovarian car-
cinoma, when taken together with our previous reported
studies on sera of patients with cancers of the breast [7],
nasopharynx [8], cervix and endometrium [9], demon-
strated that the cancer patients were aberrant in the
expression of their serum high abundance acute-phase
proteins, and this was simultaneously detected using the
gel-based proteomic analysis on whole human serum
samples without the need to deplete albumin or immu-
noglobulins. Equally intriguing is that the different types
of cancer that were studied so far appear to demonstrate
distinctive altered patterns of serum high abundance pro-
tein expression. In the case of ovarian carcinoma, this
explicitly involved elevated levels of CLU in both the
EOCa and GOCa patients and enhanced expression of
ACT only in patients with EOCa.
The different altered expression of selective high abun-
dance acute-phase serum proteins of patients with EOCa
and GOCa suggests that they may be used as protein sig-
natures that may facilitate diagnoses and/or monitoring
of the cancers. Ovarian carcinoma is usually asympto-
matic in its early stages and development. For most
patients, the disease is often widespread at the time of
diagnosis, and this is also due to the absence of sensitive
and reliable serological markers. CA125, the currently
accepted serum marker for diagnosis of ovarian carci-
noma, is limited in sensitivity as it is detected in about
50% of patients at stage 1 and 75–90% of women with
advanced stage of the disease. Moreover, it lacks specificity
as it is also elevated in 26% of non-ovarian malignancies,
14% benign ovarian disease and 9% of benign gyneco-
logic disorders [42]. Thus the need for more specific and
efficient biomarkers for diagnosis of ovarian carcinoma is
pressing. Although limited in scale, identification of the
link between selective aberrantly expressed serum pro-
teins with EOCa and GOCa as demonstrated in the
present gel-based proteomic study is a necessary prelude
to the conduct of a larger scale clinical investigation in
pursuit of additional diagnostic markers that are more
reliable and sensitive.
Conclusion
The present study demonstrated that the serum and tissue
high abundance acute-phase proteins were aberrantly
expressed in patients with EOCa and GOCa. In contrast to
control individuals, enhanced expression of CLU, AAT,
HAP and LRG was detected in all patients. However, the
levels of ACT was only enhanced in EOCa patients, while
patients with GOCa were typically characterized by ele-
vated levels of CPL but lower levels of AHS. These profiles
were different from those previously obtained from
patients with cancers of the breast, nasopharynx, cervix
and endometrium.
Methods
Subjects
Blood specimens were obtained in plain tubes from 29
patients with EOCa (ages between 24 to 65 years) and 13
GOCa patients (ages between 12 to 24 years) at the Uni-
versity of Malaya Medical and Specialist Centres. From the
29 EOCa patients, four were diagnosed with stage 1, ten
with stage 2, twelve with stage 3 and three with stage 4 of
the cancer. Only one of the GOCa patients was diagnosed
with stage 4 of the disease. Two patients were diagnosed
with stage 1, four with stage 2 and six with stage 3 of
GOCa. Samples were immediately centrifuged at 3000 g
for 10–15 minutes at 4°C. The supernatant (serum) was
collected and kept in aliquots of 50 μl. Control samples
were obtained from 30 voluntary women without cancer.
The expression of high abundance proteins in sera of con-
trol women of ages between 12 to 24 years (n = 10) was
found to be comparable to that of the control women
between the age of 24 to 65 years (n = 20) (data not
shown). Samples obtained were with consent and
approval granted by the Ethical committee (Institutional
Review Board) of the University of Malaya Medical Centre
in accordance to the ICH GCP guideline and the Declara-
tion of Helsinki.Proteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
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Two-dimensional gel electrophoresis
2-DE was performed as previously described [7-9]. Briefly,
10 μl of unfractionated whole human serum samples were
subjected to isoelectric focusing in 11 cm rehydrated pre-
cast immobilized dry strips pH 4–7 (GE Healthcare Bio-
Sciences, Uppsala, Sweden). For the second dimension,
focused samples in the strips were subjected to electro-
phoresis using the 8–18% gradient polyacrylamide gel in
the presence of sodium dodecyl sulfate (SDS-PAGE). All
samples were analyzed in duplicate.
Coomassie Blue and silver staining
The 2-DE gels were developed by silver staining as
described by Heukeshoven and Dernick [43]. For mass
spectrometric analysis, gels were stained with Coomassie
Blue according to the modified method of Shevchenko et
al. [44]. Coomassie Blue was used in this case as higher
number of peptides was recovered from the in-gel diges-
tion of Coomassie stained gel plugs compared to the plugs
from silver-stained gels.
Mass spectrometry
Highly resolved spot clusters of proteins of interest were
preliminarily identified by visual comparison with the
SWISS ExPASy standard plasma protein reference [45]
before being subjected to precise identification by mass
spectrometry using the Ettan MALDI-ToF Pro. In-gel
trypsin digestion was performed according to the method
of Shevchenko et al. [44]. Mass analyses were performed
by mixing peptide solutions with matrix solution consist-
ing of 10 mg/ml α-cyano-4-hydroxycinnamic acid in
0.5% trifluoroacetic acid (TFA) and 50% acetonitrile
(ACN) in a ratio of 1:1. The mixture (0.3 μl) was then
applied onto the sample slide. Spectrum was calibrated
using peptides included in the matrix solution, approxi-
mately 3 pmol of Ile7Ang III and hACTH 18–39 with the
expected m/z at 897.523 [(M + H)+, monoisotopic] and
2465.191 [(M + H)+, monoisotopic], respectively. Protein
spots that were not positively identified were subse-
quently sent for MS/MS analysis using a MALDI-ToF/ToF
instrument (Applied Biosystem 4700 Proteomic Ana-
lyzer) at the Australian Proteomic Analysis Facility
(APAF), Macquarie University, Sydney, Australia. Gel
plugs were kept in fresh eppendorf tubes containing small
volumes of milliQ water to ensure that they remained
hydrated prior to analysis.
Database searches
Peaklist data obtained from PMF and MS/MS analyses
were generated using the Ettan MALDI software (release
version 2.0) and 4000 Series Explorer software (release
version 3), respectively. The data were exported to the
MASCOT search engine (Matrix Science Ltd., London, UK;
release version 2.2). Search was performed against all
entries in the NCBI non redundant database (updated
April 25, 2007, containing 192489 sequences). The fol-
lowing parameters were used in the MASCOT PMF search:
(i) enzyme: trypsin, (ii) one missed cleavage allowed, (iii)
taxonomy limited to Homo sapiens, (iv) mass value:
monoisotopic, (v) peptide mass tolerance: ± 0.1 Da and
(iv) peptide charge state: 1+. The same parameters were
used in the MASCOT Ion Search, except peptide mass tol-
erance and fragment mass tolerance were set at 50 ppm
and 0.5 Da, respectively. The cut-off score for accepting
individual MS/MS spectra was >29 to indicate homology
and >38 for indication of identity.
Image analysis
The LabScan image scanner (Version 5) was used to cap-
ture and store images of 2-DE gels. The ImageMaster™ 2D
Platinum Software (Version 5) was used to evaluate the
protein profiles and present information obtained from
the 2-DE gels. To detect proteins that were differentially
expressed in sera, percentage of volume contribution
(%vol), which refers to the volume percentage of a protein
taken against the total spot volume of all proteins includ-
ing the unresolved peptides in each gel, was calculated.
Data obtained in such expression are independent of var-
iations attributed to protein loading and staining.
ELISA
Competitive ELISA was performed as previously reported
[7-9]. Concentrations of CPL, CLU, AAT, ACT, HAP and
α2-HS glycoprotein in serum samples were reflected by
their ability to inhibit the specific binding of antisera. Pri-
mary antisera (IgG fraction) comprised goat anti-human
CLU (Chemicon International, Temecula, California,
USA) and sheep anti-human ACT, AAT, AHS, CPL and
HAP (The Binding Site, Birmingham, UK). Peroxidase
conjugated donkey anti-sheep and goat IgGs (The Binding
Site, Birmingham, UK) were used as the secondary antis-
era. Assay was not performed for LRG as antiserum to the
protein was not available commercially. Enzyme activity
was revealed by addition of 3,3',5,5' tetramethylbenzidine
(Pierce, Rockford, Illinois, USA). Levels of proteins in the
test sera are proportional to the percentage inhibition of
substrate hydrolysis.
Immunohistochemical staining
A total of 17 tissue specimens, retrieved from tissue
archives (as paraffinized tissue blocks), were selected for
histopathology analysis. Two were from patients with
GOCa and 15 from confirmed EOCa specimens. Embed-
ded tissue sections that were mounted on slides contained
normal and cancerous tissues. Staining of tissues was per-
formed as previously described [7,8]. Both primary and
secondary antibodies were similar to that used in ELISA.
The intensity of the positive staining was compared to that
of the negative control tissues (substitution of the primary
antibody with buffer) and divided into three levels ofProteome Science 2008, 6:20 http://www.proteomesci.com/content/6/1/20
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intensity of expression, with diminishing scale from 3+ to
2+ and 1+. Cases were considered highly positive (3+)
when cells showed strong intensity, moderately positive
(2+) when more than 10% of the cells were stained and
weakly positive (+1) if less than 10% of the cells were
stained. Negative (-) staining was indicated for those cells
without any immunoreactivity.
Statistical analysis
Levels of proteins in the gels are presented as mean %vol
± SD (standard deviation). The Normal test (Z) was used
to analyze the significance of differences between control
subjects and patients and to examine the correlation
between the variable. P-values of less than 0.05 (p < 0.05)
were considered statistically significant.
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